The Immune Revolution: A Case for Priming, Not Checkpoint

Cancer Cell

Volumn 33, Issue 4, 2018, Pages 563-569

  Vonderheide, Robert H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

agonist; CD40; pancreatic cancer; T cell

Indexed keywords

CANCER VACCINE; CD40 ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; BLOCKING ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;

CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CROSS LINKING; HUMAN; IMMUNOSURVEILLANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, BLOCKING; B7-H1 ANTIGEN; CD40 ANTIGENS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 85044261828     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2018.03.008     Document Type: Review

References (91)

1. Ahonen, C.L., Doxsee, C.L., McGurran, S.M., Riter, T.R., Wade, W.F., Barth, R.J., Vasilakos, J.P., Noelle, R.J., Kedl, R.M., Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J. Exp. Med. 199 (2004), 775–784.
2. Ahonen, C.L., Wasiuk, A., Fuse, S., Turk, M.J., Ernstoff, M.S., Suriawinata, A.A., Gorham, J.D., Kedl, R.M., Usherwood, E.J., Noelle, R.J., Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood 111 (2008), 3116–3125.
3. Aiello, N.M., Bajor, D.L., Norgard, R.J., Sahmoud, A., Bhagwat, N., Pham, M.N., Cornish, T.C., Iacobuzio-Donahue, C.A., Vonderheide, R.H., Stanger, B.Z., Metastatic progression is associated with dynamic changes in the local microenvironment. Nat. Commun., 7, 2016, 12819.
4. Albert, M.L., Sauter, B., Bhardwaj, N., Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998), 86–89.
5. Aspord, C., Pedroza-Gonzalez, A., Gallegos, M., Tindle, S., Burton, E.C., Su, D., Marches, F., Banchereau, J., Palucka, A.K., Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J. Exp. Med. 204 (2007), 1037–1047.
6. Bailey, P., Chang, D.K., Nones, K., Johns, A.L., Patch, A.M., Gingras, M.C., Miller, D.K., Christ, A.N., Bruxner, T.J., Quinn, M.C., et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531 (2016), 47–52.
7. Bajor, D.L., Mick, R., Riese, M.J., Richman, L.P., Xu, X., Torigian, D.A., Stelekati, E., Sweeney, M., Sullivan, B., Schuchter, L.M., et al. Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma. Cancer Res., 75(15 Suppl), 2015, CT137.
8. Bajor, D.L., Xu, X., Torigian, D.A., Mick, R., Garcia, L.R., Richman, L.P., Desmarais, C., Nathanson, K.L., Schuchter, L.M., Kalos, M., Vonderheide, R.H., Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. Cancer Immunol. Res. 2 (2014), 1051–1058.
9. Balachandran, V.P., Łuksza, M., Zhao, J.N., Makarov, V., Moral, J.A., Remark, R., Herbst, B., Askan, G., Bhanot, U., Senbabaoglu, Y., et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551 (2017), 512–516.
10. Balli, D., Rech, A.J., Stanger, B.Z., Vonderheide, R.H., Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer. Clin. Cancer Res. 23 (2017), 3129–3138.
11. Beatty, G.L., Chiorean, E.G., Fishman, M.P., Saboury, B., Teitelbaum, U.R., Sun, W., Huhn, R.D., Song, W., Li, D., Sharp, L.L., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331 (2011), 1612–1616.
12. Beatty, G.L., Torigian, D.A., Chiorean, E.G., Saboury, B., Brothers, A., Alavi, A., Troxel, A.B., Sun, W., Teitelbaum, U.R., Vonderheide, R.H., O'Dwyer, P., A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin. Cancer Res. 19 (2013), 6286–6295.
13. Beatty, G.L., Winograd, R., Evans, R.A., Long, K.B., Luque, S.L., Lee, J.W., Clendenin, C., Gladney, W.L., Knoblock, D.M., Guirnalda, P.D., Vonderheide, R.H., Exclusion of T cells from pancreatic carcinomas in mice is regulated by Ly6C(low) F4/80(+) extratumoral macrophages. Gastroenterology 149 (2015), 201–210.
14. Broomfield, S.A., van der Most, R.G., Prosser, A.C., Mahendran, S., Tovey, M.G., Smyth, M.J., Robinson, B.W., Currie, A.J., Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J. Immunol. 182 (2009), 5217–5224.
15. Broz, M.L., Binnewies, M., Boldajipour, B., Nelson, A.E., Pollack, J.L., Erle, D.J., Barczak, A., Rosenblum, M.D., Daud, A., Barber, D.L., et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell, 26, 2014, 938.
16. Byrne, K.T., Vonderheide, R.H., CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. Cell Rep. 15 (2016), 2719–2732.
17. Carpenter, E.L., Mick, R., Ruter, J., Vonderheide, R.H., Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation. J. Transl. Med., 7, 2009, 93.
18. Casanovas, O., Hicklin, D.J., Bergers, G., Hanahan, D., Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8 (2005), 299–309.
19. Ciampricotti, M., Hau, C.S., Doornebal, C.W., Jonkers, J., de Visser, K.E., Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat. Med. 18 (2012), 344–346.
20. Ciampricotti, M., Vrijland, K., Hau, C.S., Pemovska, T., Doornebal, C.W., Speksnijder, E.N., Wartha, K., Jonkers, J., de Visser, K.E., Development of metastatic HER2(+) breast cancer is independent of the adaptive immune system. J. Pathol. 224 (2011), 56–66.
21. Clark, C.E., Hingorani, S.R., Mick, R., Combs, C., Tuveson, D.A., Vonderheide, R.H., Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 67 (2007), 9518–9527.
22. Coughlin, C.M., Vance, B.A., Grupp, S.A., Vonderheide, R.H., RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103 (2004), 2046–2054.
23. Coussens, L.M., Zitvogel, L., Palucka, A.K., Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 339 (2013), 286–291.
24. Dahan, R., Barnhart, B.C., Li, F., Yamniuk, A.P., Korman, A.J., Ravetch, J.V., Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective FcgammaR engagement. Cancer Cell 29 (2016), 820–831.
25. Demaria, S., Golden, E.B., Formenti, S.C., Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 1 (2015), 1325–1332.
26. DeNardo, D.G., Barreto, J.B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N., Coussens, L.M., CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16 (2009), 91–102.
27. Duan, F., Duitama, J., Al Seesi, S., Ayres, C.M., Corcelli, S.A., Pawashe, A.P., Blanchard, T., McMahon, D., Sidney, J., Sette, A., et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J. Exp. Med. 211 (2014), 2231–2248.
28. DuPage, M., Mazumdar, C., Schmidt, L.M., Cheung, A.F., Jacks, T., Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482 (2012), 405–409.
29. Durai, V., Murphy, K.M., Functions of murine dendritic cells. Immunity 45 (2016), 719–736.
30. Engelhardt, J.J., Boldajipour, B., Beemiller, P., Pandurangi, P., Sorensen, C., Werb, Z., Egeblad, M., Krummel, M.F., Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 21 (2012), 402–417.
31. Evans, R.A., Diamond, M.S., Rech, A.J., Chao, T., Richardson, M.W., Lin, J.H., Bajor, D.L., Byrne, K.T., Stanger, B.Z., Riley, J.L., et al. Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. JCI Insight, 1, 2016 e88328.
32. Feig, C., Jones, J.O., Kraman, M., Wells, R.J., Deonarine, A., Chan, D.S., Connell, C.M., Roberts, E.W., Zhao, Q., Caballero, O.L., et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. USA 110 (2013), 20212–20217.
33. Fukunaga, A., Miyamoto, M., Cho, Y., Murakami, S., Kawarada, Y., Oshikiri, T., Kato, K., Kurokawa, T., Suzuoki, M., Nakakubo, Y., et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28 (2004), e26–e31.
34. Gabrilovich, D., Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4 (2004), 941–952.
35. Gandhi, S.J., Minn, A.J., Vonderheide, R.H., Wherry, E.J., Hahn, S.M., Maity, A., Awakening the immune system with radiation: optimal dose and fractionation. Cancer Lett. 368 (2015), 185–190.
36. Grewal, I.S., Flavell, R.A., The CD40 ligand. At the center of the immune universe?. Immunol. Res. 16 (1997), 59–70.
37. Gunderson, A.J., Kaneda, M.M., Tsujikawa, T., Nguyen, A.V., Affara, N.I., Ruffell, B., Gorjestani, S., Liudahl, S.M., Truitt, M., Olson, P., et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov. 6 (2016), 270–285.
38. Harding, S.M., Benci, J.L., Irianto, J., Discher, D.E., Minn, A.J., Greenberg, R.A., Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature 548 (2017), 466–470.
39. Heath, W.R., Carbone, F.R., Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19 (2001), 47–64.
40. Hingorani, S.R., Wang, L., Multani, A.S., Combs, C., Deramaudt, T.B., Hruban, R.H., Rustgi, A.K., Chang, S., Tuveson, D.A., Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7 (2005), 469–483.
41. Ino, Y., Yamazaki-Itoh, R., Oguro, S., Shimada, K., Kosuge, T., Zavada, J., Kanai, Y., Hiraoka, N., Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS One, 8, 2013, e55146.
42. Ino, Y., Yamazaki-Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., Hiraoka, N., Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br. J. Cancer 108 (2013), 914–923.
43. Johnson, M., Fakih, M., Bendell, J., Bajor, D., Cristea, M., Tremblay, T., Trifan, O., Vonderheide, R., First in human study with the CD40 agonistic monoclonal antibody APX005M in subjects with solid tumors. J. Immunother. Cancer, 5(Suppl 3), 2017, 89.
44. Johnson, P., Challis, R., Chowdhury, F., Gao, Y., Harvey, M., Geldart, T., Kerr, P., Chan, C., Smith, A., Steven, N., et al. Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study. Clin. Cancer Res. 21 (2015), 1321–1328.
45. Kraman, M., Bambrough, P.J., Arnold, J.N., Roberts, E.W., Magiera, L., Jones, J.O., Gopinathan, A., Tuveson, D.A., Fearon, D.T., Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330 (2011), 827–830.
46. Lanzavecchia, A., Immunology. Licence to kill. Nature 393 (1998), 413–414.
47. Le, D.T., Durham, J.N., Smith, K.N., Wang, H., Bartlett, B.R., Aulakh, L.K., Lu, S., Kemberling, H., Wilt, C., Luber, B.S., et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357 (2017), 409–413.
48. Li, F., Ravetch, J.V., Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333 (2011), 1030–1034.
49. Lutz, E.R., Kinkead, H., Jaffee, E.M., Zheng, L., Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. Oncoimmunology, 3, 2014, e962401.
50. Matsushita, H., Vesely, M.D., Koboldt, D.C., Rickert, C.G., Uppaluri, R., Magrini, V.J., Arthur, C.D., White, J.M., Chen, Y.S., Shea, L.K., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482 (2012), 400–404.
51. McDonnell, A.M., Cook, A., Robinson, B.W.S., Lake, R.A., Nowak, A.K., Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters. BMC Cancer, 17, 2017, 417.
52. Messmer, D., Kipps, T.J., CD154 gene therapy for human B-cell malignancies. Ann. N. Y. Acad. Sci. 1062 (2005), 51–60.
53. Ngiow, S.F., Young, A., Blake, S.J., Hill, G.R., Yagita, H., Teng, M.W., Korman, A.J., Smyth, M.J., Agonistic CD40 mAb-driven IL12 reverses resistance to anti-PD1 in a T-cell-rich tumor. Cancer Res. 76 (2016), 6266–6277.
54. Nowak, A.K., Cook, A.M., McDonnell, A.M., Millward, M.J., Creaney, J., Francis, R.J., Hasani, A., Segal, A., Musk, A.W., Turlach, B.A., et al. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. Ann. Oncol. 26 (2015), 2483–2490.
55. Nowak, A.K., Robinson, B.W., Lake, R.A., Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 63 (2003), 4490–4496.
56. Poschke, I., Faryna, M., Bergmann, F., Flossdorf, M., Lauenstein, C., Hermes, J., Hinz, U., Hank, T., Ehrenberg, R., Volkmar, M., et al. Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. Oncoimmunology, 5, 2016, e1240859.
57. Rech, A.J., Balli, D., Mantero, A., Ishwaran, H., Nathanson, K.L., Stanger, B.Z., Vonderheide, R.H., Tumor immunity and survival as a function of alternative neopeptides in human cancer. Cancer Immunol. Res., 2018, 10.1158/2326-6066.CIR-17-0559.
58. Reck, M., Rodriguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fulop, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375 (2016), 1823–1833.
59. Remer, M., White, A., Glennie, M., Al-Shamkhani, A., Johnson, P., The use of anti-CD40 mAb in cancer. Curr. Top. Microbiol. Immunol. 405 (2017), 165–207.
60. Richman, L.P., Vonderheide, R.H., Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. Cancer Immunol. Res. 2 (2014), 19–26.
61. Roberts, E.W., Broz, M.L., Binnewies, M., Headley, M.B., Nelson, A.E., Wolf, D.M., Kaisho, T., Bogunovic, D., Bhardwaj, N., Krummel, M.F., Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 30 (2016), 324–336.
62. Rüter, J., Antonia, S.J., Burris, H.A., Huhn, R.D., Vonderheide, R.H., Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol. Ther. 10 (2010), 983–993.
63. Salmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M., Agudo, J., Tung, N., et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44 (2016), 924–938.
64. Sanchez-Paulete, A.R., Cueto, F.J., Martinez-Lopez, M., Labiano, S., Morales-Kastresana, A., Rodriguez-Ruiz, M.E., Jure-Kunkel, M., Azpilikueta, A., Aznar, M.A., Quetglas, J.I., et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. 6 (2016), 71–79.
65. Sandin, L.C., Orlova, A., Gustafsson, E., Ellmark, P., Tolmachev, V., Tötterman, T.H., Mangsbo, S.M., Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol. Res. 2 (2014), 80–90.
66. Scarlett, U.K., Cubillos-Ruiz, J.R., Nesbeth, Y.C., Martinez, D.G., Engle, X., Gewirtz, A.T., Ahonen, C.L., Conejo-Garcia, J.R., In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res. 69 (2009), 7329–7337.
67. Schreiber, R.D., Old, L.J., Smyth, M.J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331 (2011), 1565–1570.
68. Schultze, J.L., Michalak, S., Seamon, M.J., Dranoff, G., Jung, K., Daley, J., Delgado, J.C., Gribben, J.G., Nadler, L.M., CD40 activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Invest. 100 (1997), 2757–2765.
69. Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J., Schreiber, R.D., IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001), 1107–1111.
70. Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
71. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2018. CA Cancer J. Clin. 68 (2018), 7–30.
72. Spranger, S., Dai, D., Horton, B., Gajewski, T.F., Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31 (2017), 711–723 e714.
73. Stromnes, I.M., Schmitt, T.M., Hulbert, A., Brockenbrough, J.S., Nguyen, H., Cuevas, C., Dotson, A.M., Tan, X., Hotes, J.L., Greenberg, P.D., Hingorani, S.R., T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell 28 (2015), 638–652.
74. Teng, M.W., Ngiow, S.F., Ribas, A., Smyth, M.J., Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 75 (2015), 2139–2145.
75. Uno, T., Takeda, K., Kojima, Y., Yoshizawa, H., Akiba, H., Mittler, R.S., Gejyo, F., Okumura, K., Yagita, H., Smyth, M.J., Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 12 (2006), 693–698.
76. van Kooten, C., Banchereau, J., CD40-CD40 ligand. J. Leukoc. Biol. 67 (2000), 2–17.
77. van Mierlo, G.J., den Boer, A.T., Medema, J.P., van der Voort, E.I., Fransen, M.F., Offringa, R., Melief, C.J., Toes, R.E., CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl. Acad. Sci. USA 99 (2002), 5561–5566.
78. Verbrugge, I., Hagekyriakou, J., Sharp, L.L., Galli, M., West, A., McLaughlin, N.M., Duret, H., Yagita, H., Johnstone, R.W., Smyth, M.J., Haynes, N.M., Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 72 (2012), 3163–3174.
79. Vonderheide, R.H., Prospect of targeting the CD40 pathway for cancer therapy. Clin. Cancer Res. 13 (2007), 1083–1088.
80. Vonderheide, R.H., Bayne, L.J., Inflammatory networks and immune surveillance of pancreatic carcinoma. Curr. Opin. Immunol. 25 (2013), 200–205.
81. Vonderheide, R.H., Burg, J.M., Mick, R., Trosko, J.A., Li, D., Shaik, M.N., Tolcher, A.W., Hamid, O., Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology, 2, 2013, e23033.
82. Vonderheide, R.H., Dutcher, J.P., Anderson, J.E., Eckhardt, S.G., Stephans, K.F., Razvillas, B., Garl, S., Butine, M.D., Perry, V.P., Armitage, R.J., et al. Phase I study of recombinant human CD40 ligand in cancer patients. J. Clin. Oncol. 19 (2001), 3280–3287.
83. Vonderheide, R.H., Flaherty, K.T., Khalil, M., Stumacher, M.S., Bajor, D.L., Hutnick, N.A., Sullivan, P., Mahany, J.J., Gallagher, M., Kramer, A., et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25 (2007), 876–883.
84. Vonderheide, R.H., Glennie, M.J., Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19 (2013), 1035–1043.
85. White, A.L., Chan, H.T., French, R.R., Beers, S.A., Cragg, M.S., Johnson, P.W., Glennie, M.J., FcgammaRIIB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol. Immunother. 62 (2013), 941–948.
86. White, A.L., Chan, H.T., French, R.R., Willoughby, J., Mockridge, C.I., Roghanian, A., Penfold, C.A., Booth, S.G., Dodhy, A., Polak, M.E., et al. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell 27 (2015), 138–148.
87. White, A.L., Chan, H.T., Roghanian, A., French, R.R., Mockridge, C.I., Tutt, A.L., Dixon, S.V., Ajona, D., Verbeek, J.S., Al-Shamkhani, A., et al. Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187 (2011), 1754–1763.
88. Winograd, R., Byrne, K.T., Evans, R.A., Odorizzi, P.M., Meyer, A.R., Bajor, D.L., Clendenin, C., Stanger, B.Z., Furth, E.E., Wherry, E.J., Vonderheide, R.H., Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol. Res. 3 (2015), 399–411.
89. Wormann, S.M., Diakopoulos, K.N., Lesina, M., Algul, H., The immune network in pancreatic cancer development and progression. Oncogene 33 (2014), 2956–2967.
90. Zamarin, D., Holmgaard, R.B., Subudhi, S.K., Park, J.S., Mansour, M., Palese, P., Merghoub, T., Wolchok, J.D., Allison, J.P., Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med., 6, 2014, 226ra32.
91. Zippelius, A., Schreiner, J., Herzig, P., Muller, P., Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol. Res. 3 (2015), 236–244.